PMGC Holdings
PMGC Holdings reported revenue of $1 million in fiscal 2025. Its net margin was −1,313.0%. Free cash flow was −$6 million. The diluted share count rose 2049.1%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What PMGC Holdings does
PMGC Holdings is a small holding company that owns four businesses in unrelated fields and says it wants to buy more. Two of them, bought in July 2025, bring in its sales: Pacific Sun Packaging, based in San Clemente, California, designs and supplies protective trays and carriers for computer parts such as processors, memory modules and drives, for over 300 business customers in North America; and AGA Precision Systems, a California machine shop that cuts precision metal parts, including from titanium, for aerospace, defense and industrial customers.
The third, Northstrive Biosciences, is developing drugs. Its main candidate, EL-22, is a modified probiotic meant to help people keep muscle while taking weight-loss drugs such as GLP-1 medicines. It has finished an early safety trial in healthy volunteers in South Korea, and the company plans to seek approval from the US Food and Drug Administration to begin testing in patients, alone or with a partner, if it has the money. It names Novo Nordisk, Eli Lilly and Pfizer among the companies working on obesity treatments. The fourth, PMGC Capital, invests in and lends to other businesses.
The company used to sell skin-care products and sold that business in January 2025. It has 32 full-time employees. It lost $7,747,813 in 2025 and warns that there is doubt about its ability to keep operating without raising more money.
Its biggest risks, as it describes them
- Doubt about whether it can keep operating, given its continuing losses and limited cash.
- Spending far more cash than it earns, leaving it dependent on raising money from investors or lenders.
- Trouble integrating the businesses it buys, or those businesses losing key owners, staff or customers.
- Its drug candidates may fail in testing or never win approval, or it may lack the money to develop them.
Income statement
PMGC Holdings lost money in fiscal 2025: a net loss of $8 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 1 | 3 | 4 | 6 |
| Debt incl. finance leases | — | — | — | 0 |
| Net debt (negative means net cash) | — | — | — | −6 |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | — | — | 0.0x |
| Interest coverage | — | — | −4.5x | −29.1x |
| Current ratio | 2.6x | 3.8x | 3.4x | 1.7x |
| Quick ratio | 2.2x | 3.4x | — | 1.7x |
Cash flow
Projections
Project PMGC Holdings' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of PMGC Holdings reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −143.2% | — | — |
| Altman Z'' | — | −1.16 | −6.11 |
| Accruals ratio | 7.2% | −10.7% | −16.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Pass | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — | — | — |
Compare
Put PMGC Holdings side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| PMGC Holdings | FY25 | — | — | −1,080.5% | — | — | — | |
| Cardiff Oncology | FY25 | −13.2% | −8,256.3% | −6,402.5% | — | — | 2 | Compare |
| Silence Therapeutics | FY25 | −98.7% | −16,292.8% | −11,149.5% | — | — | — | Compare |
| ImageneBio | FY25 | −77.1% | −6,056.4% | — | — | — | — | Compare |
| BioRestorative Therapies | FY25 | −10.3% | −4,350.1% | −3,031.7% | — | — | — | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 1 | 2 | — | 1 |
| Revenue growth | — | 123.5% | — | — |
| Gross profit | 0 | 1 | — | 0 |
| Research and development | 0 | 0 | 0 | 0 |
| Operating income | — | — | — | — |
| Net income | −2 | −4 | −6 | −8 |
| Diluted EPS (US$) | −0.19 | −0.40 | −4,239.70 | −382.30 |
| Diluted shares (millions) | 10 | 0 | 0 | 0 |
| Cash flow | ||||
| Cash from operations | −2 | −5 | −6 | −6 |
| Capital expenditure | 0 | 0 | 0 | 0 |
| Free cash flow | −2 | −5 | −6 | −6 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 2 |
| Stock-based compensation | 0 | 0 | 0 | −0 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 1 | 3 | 4 | 6 |
| Debt incl. finance leases | — | — | — | 0 |
| Total assets | 2 | 5 | 9 | 13 |
| Total liabilities | 1 | 1 | 2 | 5 |
| Shareholders' equity | 1 | 4 | 7 | 8 |
| Margins and ratios | ||||
| Gross margin | 58.4% | 66.2% | — | 31.4% |
| Operating margin | — | — | — | — |
| Net margin | −234.9% | −251.2% | — | −1,313.0% |
| Free cash flow margin | −211.6% | −266.7% | — | −1,080.5% |
| Rule of 40 (growth + FCF margin) | — | −143.2% | — | — |
| Return on capital | — | — | — | — |
| Return on equity | — | −173.5% | −119.1% | −106.9% |
| Return on assets | — | −121.5% | −88.1% | −70.9% |
| Net debt to EBITDA | — | — | — | — |